Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-217
- Development stage
- Preclinical
- Lead developer
- Jichi Medical University
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
miR-217 is a microRNA that functions as a tumor suppressor and is notably downregulated in pancreatic ductal adenocarcinoma (PDAC). As a therapeutic candidate, miR-217 aims to restore normal microRNA levels to inhibit tumor cell proliferation and migration. It also plays a critical role in modulating the tumor microenvironment by preventing the transformation of pancreatic stellate cells (PSCs) into cancer-associated fibroblasts (CAFs), thereby reducing fibrosis and enhancing the delivery and efficacy of chemotherapeutic agents like gemcitabine and paclitaxel. Research indicates that miR-217 overexpression significantly reduces the expression of CAF markers such as alpha-smooth muscle actin (SMA) and vimentin, which are associated with chemoresistance and poor prognosis in PDAC.
- Other names
- miRNA-217miRNA217miRNA 217hsa-miR-217hsa-miR217hsa-miR 217
02
Targets
MicroRNA-217 seed-complementary motifs
Beyond the preview
Go deeper on miR-217.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-217.